<clinical_study>
<study_id>
<org_name>
  FDAOPD
</org_name>
<org_full_name>
  FDA Office of Orphan Products Development
</org_full_name>
<org_study_id>
  199/14367
</org_study_id>
<secondary_id>
  ATI-FDR001424
</secondary_id>
<nct_id>
  NCT00004500
</nct_id>
</study_id>
<brief_title>
<textblock>
  Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
</textblock>
</brief_title>
<official_title>
<textblock>
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  FDA Office of Orphan Products Development
</agency>
</lead_sponsor>
<sponsor>
<agency>
  Discovery Laboratories
</agency>
</sponsor>
</study_sponsor>
<oversight_info>
<regulatory_authority>
  United States: Federal Government
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  OBJECTIVES:
 
  I.  Determine the safety and efficacy of lucinactant in full term newborn infants with meconium aspiration syndrome.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
  PROTOCOL OUTLINE:
 
  This is a randomized, multicenter study. Patients are randomized to one of two treatment arms.
 
  Arm I: Patients receive lucinactant by bronchoalveolar lavage, into the right and left lung, followed by lung drainage. Treatment repeats when patient stabilizes or every 15 minutes for 2 courses.
 
  Arm II: Patients receive standard treatment including oxygen, conventional mechanical ventilation, sedation, paralysis, vasopressors, and alkalinization.
 
  Patients are followed for 12 months.
</textblock>
</detailed_descr>
<status_block>
<status>
  Recruiting
</status>
<date>
  2001-02
</date>
</status_block>
<start_date>
<date>
  2000-11
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date>
<date>
</date>
</last_follow_up_date>
<last_data_entry_date>
<date>
</date>
</last_data_entry_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Active Control
</design>
<design>
  Single Group Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<condition>
  Meconium Aspiration
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Lucinactant
</primary_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  PROTOCOL ENTRY CRITERIA:
 
  --Disease Characteristics--
 
  Diagnosis of meconium aspiration syndrome with respiratory distress and meconium staining at birth, in airways, or in bronchial secretions, in which there is no other major cause for respiratory distress
 
  Conventional intermittent mandatory ventilation
 
  At least 37 weeks gestational age
 
  --Patient Characteristics--
 
  Renal: No oligohydramnios with renal dysgenesis
 
  Cardiovascular: No congenital cyanotic heart disease
 
  Pulmonary: No airway anomalies; No lung hypoplasia; No pulmonary hemorrhage; No pulmonary interstitial emphysema, uncontrollable air leaks, pneumothorax, pneumomediastinum, or pneumopericardium; Oxygenation index at least 5 and no greater than 30 on a single arterial blood gas reading within 60 minutes prior to study; No diaphragmatic hernia
 
  Neurologic: No known grade III or IV intraventricular hemorrhage; No obvious CNS abnormalities or malformations
 
  Other: No hydrops fetalis immune and nonimmune; No prolonged (at least 3 weeks) rupture of the fetal membranes
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<patients>
  Yes
</patients>
<expected_enrollment>
  200
</expected_enrollment>
<gender>
  Both
</gender>
<minimum_age>
  N/A
</minimum_age>
<maximum_age>
  2 Days
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Chair
</role>
<name>
  Thomas E Wiswell
</name>
<affiliation>
<agency>
  Discovery Laboratories
</agency>
</affiliation>
</investigator>
<location>
<facility>
<name>
  Discovery Laboratories, Inc.
</name>
<address>
<city>
  Doylestown
</city>
<state>
  Pennsylvania
</state>
<zip>
  18901
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Thomas E Wiswell
</name>
<phone>
  215-340-4699
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<keyword>
  cardiovascular and respiratory diseases
</keyword>
<keyword>
  meconium aspiration syndrome
</keyword>
<keyword>
  rare disease
</keyword>
<initial_release_date>
  1999-10-18
</initial_release_date>
<last_release_date>
  2005-06-23
</last_release_date>
</clinical_study>
